392 related articles for article (PubMed ID: 24615776)
41. Idelalisib--a PI3Kδ inhibitor for B-cell cancers.
Fruman DA; Cantley LC
N Engl J Med; 2014 Mar; 370(11):1061-2. PubMed ID: 24620870
[No Abstract] [Full Text] [Related]
42. Management of adverse events associated with idelalisib treatment: expert panel opinion.
Coutré SE; Barrientos JC; Brown JR; de Vos S; Furman RR; Keating MJ; Li D; O'Brien SM; Pagel JM; Poleski MH; Sharman JP; Yao NS; Zelenetz AD
Leuk Lymphoma; 2015; 56(10):2779-86. PubMed ID: 25726955
[TBL] [Abstract][Full Text] [Related]
43. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
Burris HA; Flinn IW; Patel MR; Fenske TS; Deng C; Brander DM; Gutierrez M; Essell JH; Kuhn JG; Miskin HP; Sportelli P; Weiss MS; Vakkalanka S; Savona MR; O'Connor OA
Lancet Oncol; 2018 Apr; 19(4):486-496. PubMed ID: 29475723
[TBL] [Abstract][Full Text] [Related]
44. A Phase Ib Study of Single-Agent Idelalisib Followed by Idelalisib in Combination with Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
Borazanci E; Pishvaian MJ; Nemunaitis J; Weekes C; Huang J; Rajakumaraswamy N
Oncologist; 2020 Nov; 25(11):e1604-e1613. PubMed ID: 32356383
[TBL] [Abstract][Full Text] [Related]
45. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
46. A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO-idel).
Eyre TA; Preston G; Kagdi H; Islam A; Nicholson T; Smith HW; Cursley AP; Ramroth H; Xing G; Gu L; Rajakumaraswamy N; Fegan C
Br J Haematol; 2021 Jul; 194(1):69-77. PubMed ID: 34121184
[TBL] [Abstract][Full Text] [Related]
47. Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential.
Barrientos JC
Onco Targets Ther; 2016; 9():2945-53. PubMed ID: 27274288
[TBL] [Abstract][Full Text] [Related]
48. Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper.
Cuneo A; Barosi G; Danesi R; Fagiuoli S; Ghia P; Marzano A; Montillo M; Poletti V; Viale P; Zinzani PL
Hematol Oncol; 2019 Feb; 37(1):3-14. PubMed ID: 30187496
[TBL] [Abstract][Full Text] [Related]
49. Combination trial of duvelisib (IPI-145) with rituximab or bendamustine/rituximab in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia.
Flinn IW; Cherry MA; Maris MB; Matous JV; Berdeja JG; Patel M
Am J Hematol; 2019 Dec; 94(12):1325-1334. PubMed ID: 31490009
[TBL] [Abstract][Full Text] [Related]
50. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.
Bannerji R; Arnason JE; Advani RH; Brown JR; Allan JN; Ansell SM; Barnes JA; O'Brien SM; Chávez JC; Duell J; Rosenwald A; Crombie JL; Ufkin M; Li J; Zhu M; Ambati SR; Chaudhry A; Lowy I; Topp MS
Lancet Haematol; 2022 May; 9(5):e327-e339. PubMed ID: 35366963
[TBL] [Abstract][Full Text] [Related]
51. Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma.
Bennani NN; LaPlant BR; Ansell SM; Habermann TM; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Colgan JP; Markovic SN; Nowakowski GS; Macon WR; Reeder CB; Mikhael JR; Northfelt DW; Ghobrial IM; Witzig TE
Am J Hematol; 2017 May; 92(5):448-453. PubMed ID: 28211162
[TBL] [Abstract][Full Text] [Related]
52. Haematological cancer: idelalisib-targeting PI3Kδ in patients with B-cell malignancies.
Burger JA; Okkenhaug K
Nat Rev Clin Oncol; 2014 Apr; 11(4):184-6. PubMed ID: 24642682
[TBL] [Abstract][Full Text] [Related]
53. Phase II trial of irinotecan (CPT-11) in relapsed or refractory non-Hodgkin's lymphomas.
Ribrag V; Koscielny S; Vantelon JM; Fermé C; Rideller K; Carde P; Bourhis JH; Munck JN
Leuk Lymphoma; 2003 Sep; 44(9):1529-33. PubMed ID: 14565655
[TBL] [Abstract][Full Text] [Related]
54. Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial.
Matasar MJ; Capra M; Özcan M; Lv F; Li W; Yañez E; Sapunarova K; Lin T; Jin J; Jurczak W; Hamed A; Wang MC; Baker R; Bondarenko I; Zhang Q; Feng J; Geissler K; Lazaroiu M; Saydam G; Szomor Á; Bouabdallah K; Galiulin R; Uchida T; Soler LM; Cao A; Hiemeyer F; Mehra A; Childs BH; Shi Y; Zinzani PL
Lancet Oncol; 2021 May; 22(5):678-689. PubMed ID: 33848462
[TBL] [Abstract][Full Text] [Related]
55. The pharmacokinetics and safety of idelalisib in subjects with severe renal impairment.
Jin F; Robeson M; Zhou H; Hisoire G; Ramanathan S
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1133-41. PubMed ID: 26526983
[TBL] [Abstract][Full Text] [Related]
56. Mature response data from a phase 2 study of PI3K-delta inhibitor idelalisib in patients with double (rituximab and alkylating agent)-refractory indolent B-cell non-Hodgkin lymphoma (iNHL).
Clin Adv Hematol Oncol; 2014 Feb; 12(2 Suppl 6):8-9. PubMed ID: 24870874
[No Abstract] [Full Text] [Related]
57. Efficacy and safety of idelalisib for the treatment of indolent B-cell malignancies.
Smolewski P; Rydygier D
Expert Opin Pharmacother; 2020 Oct; 21(15):1915-1926. PubMed ID: 32686971
[TBL] [Abstract][Full Text] [Related]
58. Clinical drug interaction profile of idelalisib in healthy subjects.
Jin F; Robeson M; Zhou H; Moyer C; Wilbert S; Murray B; Ramanathan S
J Clin Pharmacol; 2015 Aug; 55(8):909-19. PubMed ID: 25760671
[TBL] [Abstract][Full Text] [Related]
59. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.
Witzig TE; Wiernik PH; Moore T; Reeder C; Cole C; Justice G; Kaplan H; Voralia M; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Vose JM
J Clin Oncol; 2009 Nov; 27(32):5404-9. PubMed ID: 19805688
[TBL] [Abstract][Full Text] [Related]
60. Idelalisib immune-related toxicity is associated with improved treatment response.
Wagner-Johnston ND; Sharman J; Furman RR; Salles G; Brown JR; Robak T; Gu L; Xing G; Chan RJ; Rajakumaraswamy N; Gopal AK
Leuk Lymphoma; 2021 Dec; 62(12):2915-2920. PubMed ID: 34319205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]